Immunoglobulin E specific for Olea europaea pollen allergens (Olive pollen-specific IgE)

IgE antibodies specific for Olea europaea pollen allergens are the primary immunological mediators of olive pollen allergy, a significant cause of seasonal respiratory disease in Mediterranean regions [1.3.2, 1.4.1]. These antibodies are produced by the immune system in response to allergens such as Ole e 1, the major protein component of olive tree pollen [1.1.1, 1.3.3]. Once produced, these specific IgE molecules bind to high-affinity receptors (FcεRI) on the surface of mast cells and basophils, sensitizing the individual [1.4.4]. Upon re-exposure to olive pollen, the allergens cross-link the surface-bound IgE, triggering the rapid release of inflammatory mediators like histamine and leukotrienes [1.4.1, 1.4.4]. This cascade results in the symptoms of allergic rhinitis, conjunctivitis, and in some cases, severe asthma [1.2.1, 1.3.2]. Therapeutic management often involves the use of omalizumab, a monoclonal antibody that binds to the Fc region of IgE to prevent its interaction with receptors [1.2.3, 1.2.4]. Additionally, allergen-specific immunotherapy (AIT) is used to induce immune tolerance by gradually exposing the patient to olive pollen extracts, thereby reducing the levels of specific IgE and increasing protective IgG4 antibodies [1.1.4, 1.3.2]. Novel approaches also include the development of hypoallergenic recombinant allergens and peptide-based vaccines to improve the safety and efficacy of treatment [1.1.3, 1.3.5].

Other names

Olea europaea-specific IgEOlive pollen-specific IgEOle e 1-specific IgEAnti-olive pollen IgEOlive pollen sIgE

Omalizumab binds to the Fc region (Cε3 domain) of circulating IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the allergic cascade [1.2.3, 1.4.4]. Allergen-specific immunotherapy (AIT) works by inducing allergen-specific IgG4 'blocking' antibodies that compete with IgE for allergen binding and by promoting T-cell tolerance [1.3.2, 1.1.4].